Skip to Main Content

Paper Details

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Br J Cancer
8
2018
BRCA, BRCA1/2, BRCA1/2 mutations, BRCA2, CONCLUSIONS PSA, PSA, PSAV, PSAs, PrCa, PrCas, Prostate-specific antigen, cancer, men, participants, prostate cancer
Author NameAffiliation
Elizabeth BancroftThe Institute of Cancer Research
Elizabeth BancroftRoyal Marsden NHS Foundation Trust
Tokhir DadaevThe Institute of Cancer Research
Christi J van AsperenLeiden University Medical Center
Lambertus A KiemeneyRadboud University Medical Center
Cezary CybulskiInternational Hereditary Cancer Center, Pomeranian Medical University
Susan M DomchekBasser Research Center, University of Pennsylvania
Louise IzattGuy's Hospital
William D FoulkesMcGill University
William D FoulkesMcGill University
Judy KirkWestmead Hospital
Judy KirkThe Westmead Institute for Medical Research
Nicholas PachterKing Edward Memorial Hospital
Nicholas PachterUniversity of Western Australia
Declan G MurphyUniversity of Melbourne
Daniel LeongamornlertThe Institute of Cancer Research
Anna NewlinCenter for Medical Genetics, NorthShore University HealthSystem
Anna NewlinCenter for Medical Genetics, NorthShore University HealthSystem
Christopher S Foster
Henrik Gr??nbergUniversity Hospital
Henrik Gr??nbergUniversity Hospital
Freddie C HamdyChurchill Hospital
Freddie C HamdyUniversity of Oxford
Vincent KhooRoyal Marsden NHS Foundation Trust
Jan LubinskiInternational Hereditary Cancer Center, Pomeranian Medical University
Jan LubinskiInternational Hereditary Cancer Center, Pomeranian Medical University
Zsofia Kote-JaraiThe Institute of Cancer Research
Rosalind A EelesThe Institute of Cancer Research
Rosalind A EelesRoyal Marsden NHS Foundation Trust
  • 1 - 29

Datasets

Release 1.2